


글로벌 제약사 파이프라인 분석

- AbbVie -

2022. 08.

국가신약개발사업단


• 질환별 파이프라인



abbvie

질환분야	개수	비중
Oncology	33	48.5%
Immunology	14	21%
Neuroscience	10	15%
Ophthalmology	5	7%
Infectious	3	4%
Respiratory	1	1.5%
Cardiovascular	1	1.5%
Metabolic	1	1.5%
합계	68개	100%

• 물질별 파이프라인



abbvie

물질	개수	비중
Small molecules	30	44%
Antibody	23	34%
ADC	9	13%
Protein	2	3%
Gene therapy	2	3%
Cell therapy	1	1.5%
Others	1	1.5%
합계	68개	100%

• 상세 파이프라인

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
1	Cardiovascular	Phase 2	AGN-151607		gemibotulinu mtoxin A	Atrial fibrillation	Antibody	SNAP-25	SNAP-25 inhibitor	Mono	-
2	Immunology	Registration	ABBV-066	Skyrizi	risankizumab	Crohn's disease	Antibody	IL-23	IL-23 inhibitor	Mono	-
3	Immunology	Registration	ABT-494	Rinvoq	upadacitinib	Axial spondyloarthritis	Small molecules	JAK1	JAK1 inhibitor	Mono	-
4	Immunology	Phase 3	ABBV-066	Skyrizi	risankizumab	Ulcerative Colitis	Antibody	IL-23	IL-23 inhibitor	Mono	-
5	Immunology	Phase 3	ABT-494	Rinvoq	upadacitinib	Crohn's disease	Small molecules	JAK1	JAK1 inhibitor	Mono	-
6	Immunology	Phase 3	ABT-494	Rinvoq	upadacitinib	Giant cell arteritis	Small molecules	JAK1	JAK1 inhibitor	Mono	-
7	Immunology	Phase 3	ABT-494	Rinvoq	upadacitinib	Takayasu arteritis	Small molecules	JAK1	JAK1 inhibitor	Mono	-
8	Immunology	Phase 2	ABBV-154			Polymyalgia rheumatica	ADC	TNF	TNF inhibitor	Mono	-
9	Immunology	Phase 2	ABBV-154			Rheumatoid arthritis	ADC	TNF	TNF inhibitor	Mono	-
10	Immunology	Phase 2	ABBV-154			Crohn's disease	ADC	TNF	TNF inhibitor	Mono	-
11	Immunology	Phase 2	ABBV-157			Immune-mediated disease	Small molecules	RORγT	RORγT inhibitor	Mono	-
12	Immunology	Phase 2	ABBV-599			Systemic Lupus Erythematosus	Small molecules	BTK, JAK1	BTK, JAK1 inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
13	Immunology	Phase 2	ABT-981		lutikizumab	Hidradenitis suppurativa	Small molecules	IL-1a/1b	IL-1a/1b antagonist	Mono	-
14	Immunology	Phase 2	ALPN-101		acazicolcept	Systemic Lupus Erythematosus	Protein	CD28/ICOS	CD28/ICOS antagonist	Mono	Alpine
15	Immunology	Phase 1	ABBV-668			Immune-mediated disease	Small molecules	RIPK1	RIPK1 inhibitor	Mono	-
16	Infectious	Phase 3	PF-06947387		aztreonam/avi bactam	Complicate gram-negative infections	Small molecules	PBP3	PBP3 inhibitor	Combination	Pfizer
17	Infectious	Phase 2	ABBV-4083			Filarial Diseases	Small molecules	Wolbachia	N/A	Mono	-
18	Infectious	Phase 1	ABBV-1882			HIV	Antibody	Protectin D1	Protectin D1 inhibitor	Mono	-
19	Metabolic	Phase 2			armour thyroid	Hypothyroidism	Others	T3T4	N/A	Mono	-
20	Neuroscience	Registration		Vraylar	cariprazine	Adjunctive major depressive disorder	Small molecules	DRD2, DRD3	DRD2, DRD3 agonist	Mono	Gedeon Richter
21	Neuroscience	Phase 3	ABBV-951		foslevodopa	Parkinson's disease	Small molecules	Dopamine receptor	Dopamine receptor agonist	Mono	-
22	Neuroscience	Phase 3		Qulipta	atogepant	Chronic migraine prophylaxis	Small molecules	CGRP	CGRP receptor antagonist	Mono	-
23	Neuroscience	Phase 2	ABT-555		elezanumab	Spinal cord injury	Antibody	RGMa	RGMa inhibitor	Mono	-
24	Neuroscience	Phase 2	ABT-555		elezanumab	Acute ischemic stroke	Antibody	RGMa	RGMa inhibitor	Mono	-
25	Neuroscience	Phase 2	AL002			Alzheimer's disease	Antibody	TREM2	TREM2 agonist	Mono	Alector

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
26	Neuroscience	Phase 1	ABBV-0805			Parkinson's disease	Antibody	SNCA	SNCA inhibitor	Mono	-
27	Neuroscience	Phase 1	ABBV-916			Alzheimer's disease	Antibody	AβpE3	N/A	Mono	-
28	Neuroscience	Phase 1	ABBV-CLS-7262			Amyotrophic Lateral Sclerosis	Small molecules	eIF2B	eIF2B activator	Mono	Calico Life Sciences
29	Neuroscience	Phase 1	AL003			Alzheimer's disease	Antibody	SIGLEC3	SIGLEC3 inhibitor	Mono	Alector
30	Oncology	Phase 3	ABT-199	Venclexta	venetoclax	Myelodysplastic syndrome	Small molecules	BCL2	BCL2 inhibitor	Mono	Roche
31	Oncology	Phase 3	ABT-199	Venclexta	venetoclax	Multiple myeloma	Small molecules	BCL2	BCL2 inhibitor	Mono	Roche
32	Oncology	Phase 3	ABT-888		veliparib	Breast cancer	Small molecules	PARP	PARP inhibitor	Mono	-
33	Oncology	Phase 3	ABT-888		veliparib	Ovarian cancer	Small molecules	PARP	PARP inhibitor	Mono	-
34	Oncology	Phase 3	Gen-3013		epcoritamab	Multiple hematological B cell Malignancies	Antibody	CD3/CD20	Bispecific antibody (CD3,CD20)	Mono	Genmab
35	Oncology	Phase 3	PCI-32765	Imbruvica	ibrutinib	Follicular lymphoma	Small molecules	BTK	BTK inhibitor	Mono	-
36	Oncology	Phase 3	PCI-32765	Imbruvica	ibrutinib	Mantle cell lymphoma	Small molecules	BTK	BTK inhibitor	Mono	-
37	Oncology	Phase 3		Navitoclax	navitoclax dihydrochloride	Myelofibrosis	Small molecules	BCL-XL/BCL-2	BCL-XL/BCL-2 inhibitor	Mono	-
38	Oncology	Phase 2	ABBV-399		telisotuzumab vedotin	NSCLC	ADC	cMet	Cytotoxic to cells expressing cMet	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
39	Oncology	Phase 2	ABBV-CX-2029			Solid and hematologic tumors	ADC	CD71	CD71 antagonist	Mono	CytomX
40	Oncology	Phase 1	ABBV-011			Small cell lung cancer	ADC	N/A	N/A	Mono	-
41	Oncology	Phase 1	ABBV-151			Solid tumors	Antibody	GARP-TGF-β1	GARP-TGF-β1 inhibitor	Mono	-
42	Oncology	Phase 1	ABBV-155		mirzotamab cl ezutoclax	Solid and hematologic tumors	ADC	BCL-XL	Cytotoxic to cells expressing BCL-XL	Mono	-
43	Oncology	Phase 1	ABBV-181		budigalimab	Solid tumors	Antibody	PD-1	PD-1 antagonist	Mono	-
44	Oncology	Phase 1	ABBV-368			Solid tumors	Antibody	OX40	OX40 agonist	Mono	-
45	Oncology	Phase 1	ABBV-383			Multiple myeloma	Antibody	CD3/BCMA	Bispecific antibody (CD3,BCMA)	Mono	-
46	Oncology	Phase 1	ABBV-400			Solid tumors	ADC	cMet	Cytotoxic to cells expressing cMet	Mono	-
47	Oncology	Phase 1	ABBV-514			Solid tumors	Antibody	Chemokine receptor	Chemokines antagonist	Combination	-
48	Oncology	Phase 1	ABBV-621		eftozanermin alfa	Solid and hematologic tumors	Protein	Tumour necrosis factor-related apoptosis-inducing ligand(TRAIL)	TRAIL agonist	Mono	-
49	Oncology	Phase 1	ABBV-637			Solid tumors	Antibody	EGFR	Cytotoxic to cells expressing EGFR	Mono	-
50	Oncology	Phase 1	ABBV-647		cofetuzumab pelidotin	Solid tumors	ADC	PTK7	PTK7 inhibitor	Mono	-
51	Oncology	Phase 1	ABBV-744			Myelofibrosis	Small molecules	BRD2, BRD4	BRD2, BRD4 inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
52	Oncology	Phase 1	ABBV-927			Solid tumors	Antibody	CD40	CD40 agonist	Mono	-
53	Oncology	Phase 1	ABBV-CLS-484			Solid tumors	Small molecules	PTPN2	PTPN2 inhibitor	Mono	Calico Life Sciences
54	Oncology	Phase 1	ABBV-CLS-579			Solid tumors	Small molecules	PTPN2	PTPN2 inhibitor	Mono	Calico Life Sciences
55	Oncology	Phase 1	ABBV-IMAB-TJC4		lemzoparlimab	Hematologic malignancies and solid tumors	Antibody	CD47	CD47 inhibitor	Mono	-
56	Oncology	Phase 1	ABT-199	Venclexta	venetoclax	Acute Lymphocytic Leukemia	Small molecules	BCL2	BCL2 inhibitor	Mono	Roche
57	Oncology	Phase 1	CCW702			Prostate cancer	Antibody	CD3/PSMA	Bispecific antibody (CD3,PSMA)	Mono	Calibr
58	Oncology	Phase 1	CLBR001 + SWI019			Hematologic tumors	Cell therapy	CD19	Cytotoxic to cells expressing CD19	Combination	Calibr
59	Oncology	Phase 1	Gen-3009			Hematological malignancies	Antibody	CD37	Bispecific antibody (2 overlapping CD37)	Mono	Genmab
60	Oncology	Phase 1	HPN-217			Multiple myeloma in relapse	Antibody	BCMA	Cytotoxic to cells expressing BCMA	Mono	Harpoon Therapeutics
61	Oncology	Phase 1	JAB-3068, JAB-3312			Solid tumors	Small molecules	SHP2	SHP2 inhibitor	Mono	Jacobio Pharmaceuticals
62	Oncology	Phase 1	TTX-030			Solid tumors	Antibody	CD39	CD39 inhibitor	Mono	Trishula Therapeutics
63	Ophthalmology	Phase 3	RGX-314			Wet Age-related Macular Degeneration	Gene therapy	VEGF	VEGF inhibitor	Mono	RegenxBio

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
64	Ophthalmology	Phase 2	AGN-231868			Dry Eye	Small molecules	Chemokine receptor	Chemokines antagonist	Mono	-
65	Ophthalmology	Phase 2	AGN-242428			Dry Eye	Small molecules	RORC	RORC inhibitor	Mono	-
66	Ophthalmology	Phase 2	RGX-314			Diabetic Retinopathy	Gene therapy	VEGF	VEGF inhibitor	Mono	RegenxBio
67	Ophthalmology	Phase 1	AGN-241622			Presbyopia	Small molecules	adrenergic receptor alpha2(ADRA2)	ADRA2 agonist	Mono	-
68	Respiratory	Phase 2	CF-combo		galicافتor+ CLPG2451+ GLPG2737	Cystic fibrosis	Small molecules	CFTR	CFTR activator	Combination	-

자료: AbbVie 홈페이지, BioCentury, GlobalData